Avalyn Pharma Inc. (NASDAQ:AVLN) Stock Now Rated "Moderate Buy" by Wall Street Analysts

Key Points

• Avalyn Pharma has a consensus “Moderate Buy” rating from six analysts, with two buy, two strong-buy, one hold, and one sell recommendation. The average 12-month price target is $60, substantially above the reported $28.49 share price.
• The stock recently traded near the lower end of its 52-week range, with a market capitalization of approximately $1.26 billion. Avalyn reported a quarterly loss of $0.98 per share, beating estimates for a $1.03 loss.
• Institutional investors established sizable new positions during the second quarter, including Montanova Capital’s $82.4 million stake and Braidwell’s $26.4 million position. The clinical-stage company is developing inhaled therapies for serious lung diseases, led by its AP01 treatment for idiopathic pulmonary fibrosis.

Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $60.00.

Several analysts have commented on AVLN shares. Weiss Ratings started coverage on shares of Avalyn Pharma in a research report on Thursday, August 13th. They issued a "sell (d+)" rating for the company. Wall Street Zen lowered shares of Avalyn Pharma from a "hold" rating to a "sell" rating in a research note on Sunday, September 20th. Finally, Morgan Stanley increased their target price on shares of Avalyn Pharma from $53.00 to $57.00 and gave the stock an "overweight" rating in a research report on Thursday, August 13th.

Avalyn Pharma Price Performance

AVLN stock opened at $28.49 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 33.12 and a quick ratio of 33.12. The firm has a market capitalization of $1.26 billion and a price-to-earnings ratio of -1.25. Avalyn Pharma has a 52-week low of $24.15 and a 52-week high of $40.17. The company's 50 day moving average price is $33.54.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) earnings per share for the quarter, beating analysts' consensus estimates of ($1.03) by $0.05. Sell-side analysts predict that Avalyn Pharma will post -3.81 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Montanova Capital LLC acquired a new position in shares of Avalyn Pharma in the second quarter valued at $82,402,000. Braidwell LP acquired a new stake in Avalyn Pharma during the second quarter worth $26,382,000. State Street Corp bought a new stake in Avalyn Pharma in the 2nd quarter valued at $10,501,000. Finally, Bank of New York Mellon Corp bought a new stake in Avalyn Pharma in the 2nd quarter valued at $1,321,000.

Avalyn Pharma Company Profile

Avalyn Pharma is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious and progressive pulmonary diseases. The company is working to deliver established antifibrotic medicines directly to the lungs through proprietary inhalation technologies, with the goal of improving treatment and potentially reducing systemic exposure and related side effects.

Avalyn's lead program, AP01, is an inhaled formulation of pirfenidone being developed for patients with idiopathic pulmonary fibrosis, a chronic lung disease characterized by progressive scarring and declining respiratory function.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.